Epitalon
Epithalon · pineal tetrapeptide
Synthetic pineal tetrapeptide. Not FDA-approved; evidence is largely preclinical.
Also known as · Senolytic peptide
FOXO4-DRI
Synthetic FOXO4-targeting peptide. Not FDA-approved; evidence is preclinical.
What it is
FOXO4-DRI (FOXO4 D-Retro-Inverso) is a synthetic peptide designed to interfere with the interaction between FOXO4 and p53, two proteins involved in cellular senescence pathways. The peptide was designed to trigger apoptosis in senescent cells while sparing healthy cells, placing it in the “senolytic” class of experimental compounds. FOXO4-DRI is not FDA-approved for any use in the United States.
The senolytic concept emerged from research showing that senescent cells (cells that have permanently exited the cell cycle but remain metabolically active) accumulate with age and are thought to contribute to age-related dysfunction through their pro-inflammatory secretory profile (the SASP — senescence-associated secretory phenotype).
Mechanism of action
Proposed mechanisms come from laboratory and animal research. FOXO4-DRI has been reported to compete with native FOXO4 for binding to p53, disrupting a complex that is thought to protect senescent cells from apoptosis. In laboratory and animal studies, disruption of this complex was associated with apoptotic clearance of senescent cells. The “D-retro-inverso” structural modification is intended to stabilize the peptide and allow intracellular delivery.
Clinical evidence
FOXO4-DRI has been studied primarily in preclinical models. In animal studies (mainly in mice), FOXO4-DRI administration was associated with:
- Reduction in senescent cell burden
- Changes in physical performance measures in aged mice
- Changes in markers of kidney function
- Hair regrowth in some experimental conditions
Human clinical trials are absent or very limited, and the effectiveness and safety of FOXO4-DRI in people have not been established. The senolytic concept is being explored more broadly with other compounds, with most human research using those agents rather than FOXO4-DRI.
Why we don’t prescribe it at The Tide
The Tide does not prescribe FOXO4-DRI. It has not been evaluated in human clinical trials, and its effectiveness and safety in people are unknown. Senolytics remain an active area of laboratory research.
Side effects and contraindications
Human safety data are essentially absent, and long-term effects are unknown. There are theoretical concerns about disrupting p53-related cellular regulation in non-senescent cells. Products sold outside regulated channels (e.g., “research peptides”) may vary in purity, dose, and sterility.